What is a desmoid tumor? A desmoid tumor is a rare fibrous growth that can start in the arms, legs, or torso (body). They most commonly grow in the abdomen (belly). These tumors start in connective ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

The results of the DeFi trial of nirogacestat in 142 adults with progressing desmoid tumours showed a significant 71% improvement with the drug on progression-free survival (PFS) compared to ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...

Two years later, Nansi, from Criccieth in Gwynedd, was diagnosed with desmoid-type fibromatosis (DF), a rare type of soft tissue tumour. "The doctors should have listened to me. I’m her mother ...

The market opportunity appears to be larger than previously estimated, suggesting significant potential for revenue growth as Ogsiveo becomes a standard of care in treating desmoid tumors. In another ...

Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a med ...

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has been assigned an average recommendation of “Buy” from the six brokerages ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...